(Q41509823)

English

Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice

scientific article published on December 1993

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 October 2017

Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice (English)

1 reference

Europe PubMed Central

1 October 2017

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

1 October 2017

author name string

J Pinski

1

1 reference

Europe PubMed Central

1 October 2017

G Halmos

3

1 reference

Europe PubMed Central

1 October 2017

K Szepeshazi

4

1 reference

Europe PubMed Central

1 October 2017

language of work or name

0 references

publication date

1 December 1993

1 reference

Europe PubMed Central

1 October 2017

International Journal of Cancer

1 reference

Europe PubMed Central

1 October 2017

55

1 reference

Europe PubMed Central

1 October 2017

6

1 reference

Europe PubMed Central

1 October 2017

963-967

1 reference

Europe PubMed Central

1 October 2017

Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal d-Trp or d-Tpi

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

LIGAND: A versatile computerized approach for characterization of ligand-binding systems

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Growth factor involvement and oncogene expression in prostatic tumours

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Bombesin stimulates growth of human prostatic cancer cells in vitro

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910550615

Identifiers

10.1002/IJC.2910550615

1 reference

Europe PubMed Central

1 October 2017

1 reference

Europe PubMed Central

1 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41509823&oldid=1922534804"